PRQR
What one share of ProQR Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company advancing a pipeline (Figure 1) of RNA editing therapeutics based on our proprietary Axiomer RNA-editing platform. Our lead program, AX-0810 for cholestatic diseases targeting na-taurocholate cotransporting polypeptide (“NTCP”), is currently being evaluated in a Phase 1 clinical trial in healthy volunteers.
ProQR Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.17 |
|---|---|
| Profit | −$0.45 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.58 |
| Cash and investments | $1.03 |
| Debt | $0.05 |
| Book value | $0.55 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$1.85 | $0.12 | −$1.74 | — | $2.40 |
| 2017 | — | −$1.94 | $0.01 | −$1.56 | — | $1.48 |
| 2018 | — | −$1.28 | $0.01 | −$1.00 | — | $2.74 |
| 2019 | — | −$1.54 | $0.02 | −$1.22 | — | $2.13 |
| 2020 | — | −$1.06 | $0.02 | −$1.09 | — | $1.29 |
| 2021 | $0.02 | −$1.12 | $0.01 | −$0.49 | — | $1.81 |
| 2022 | $0.05 | −$0.95 | $0.01 | −$1.02 | — | $0.89 |
| 2023 | $0.09 | −$0.38 | $0.02 | $0.27 | — | $0.56 |
| 2024 | $0.24 | −$0.35 | $0.02 | −$0.48 | — | $0.87 |
| 2025 | $0.17 | −$0.45 | $0.01 | −$0.58 | — | $0.55 |